Consultant Physician

Recommendations

Info

Financial Conflicts of Interest Checklist 2010 For funders, journal editors and other stakeholders with a standardized tool Paula A Rochon, MD, MPH, is senior scientist at Women’s College Research Institute at Women’s College Hospital, Toronto SECTION 2 : STUDY INFORMATION MODULE B: FUNDER PROFILE MODULE C: CONTRACT PROFILE MODULE D: STUDY TEAM AND FUNDER RELATIONSHIP PROFILE
Financial Conflicts of Interest Checklist 2010 For funders, journal editors and other stakeholders with a standardized tool Paula A Rochon, MD, MPH, is senior scientist at Women’s College Research Institute at Women’s College Hospital, Toronto SECTION 3 : PERSONAL FINANCIAL INFORMATION MODULE E: FINANCIAL PROFILE
Page 1 and 2: Credibility and Evidence Based Natu
Page 3 and 4: Aim of presentation • How far the
Page 5 and 6: The relationship between exposure t
Page 7 and 8: Conflict of interest (COI) The trad
Page 9 and 10: Candidate List of Categories of Fin
Page 11 and 12: Actual or reasonably perceived conf
Page 13 and 14: Physician relationships with the in
Page 15 and 16: Physician Relationships With The In
Page 17 and 18: Physician Relationships With The In
Page 19 and 20: Concerns Regarding Physician Relati
Page 21 and 22: Ethics And Compliance Payments to
Page 23 and 24: Ethics And Compliance Biopharmaceut
Page 25 and 26: Guidelines For Physician-Pharmaceut
Page 27 and 28: Financial Conflicts of Interest Che
Page 29: Financial Conflicts of Interest Che
Page 33 and 34: Drug surveillance and a real world
Page 35 and 36: Systems for assessment of postmarke
Page 37 and 38: Systems for assessment of postmarke
Page 39 and 40: Exposures to information from pharm
Page 41 and 42: Why we as prescribers still meet ph
Page 43 and 44: This is how each of the companies l
Page 45 and 46: After two decades of decimation, on
Page 47 and 48: Incretin Drugs Contribute Heavily t
Page 49 and 50: A Clouded Future For Big Pharma's B
Page 51 and 52: The largest health fraud settlement
Page 53 and 54: Use of drugs and its budgetary impl
Page 55 and 56: Key functions of drug regulatory ag
Page 57 and 58: Relationships Between Authors of Cl
Page 59 and 60: Conflicts (Dualities) of interest i
Page 61 and 62: Conflicts (Dualities) of interest a
Page 63 and 64: Cross-sectional survey of 192 autho
Page 65 and 66: Clinical practice guidelines for di
Page 67 and 68: Hierarchy of evidence-based medicin
Page 69 and 70: Criteria for assigning levels of ev
Page 71 and 72: Criteria for assigning grades of re
Page 73 and 74: Criteria for assigning levels of ev
Page 75 and 76: Meta-analysis may not consider COI
Page 77 and 78: Financial disclosures in RCT’s* 5
Page 79 and 80: Large trials that compared clinical
Page 81 and 82:
HBA1C targets suggested by differen
Page 83 and 84:
The goal for A1c may not be safely
Page 85 and 86:
A Patient- Centered Approach to Typ
Page 87 and 88:
According to subset analyses from a
Page 89 and 90:
Approach to management of hyperglyc
Page 91 and 92:
VA/DoD Clinical Practice Guideline
Page 93 and 94:
What is Algorithm (in guidelines)?
Page 95 and 96:
Types of medical practice setting
Page 97 and 98:
In summary why we need clinical pra
Page 99 and 100:
Dissemination and implementation an
Page 101 and 102:
Clinical Practice Guidelines (CPGs)
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Personalized medicine Using a pers
Page 109 and 110:
Delaying the Onset of Type 2 Diabet
Page 111 and 112:
Intervention studies on the prevent
Page 113 and 114:
Management of hyperglycaemia in typ
Page 115 and 116:
General recommendations for managem
Page 117 and 118:
ADA-EASD Position Statement: Manage
Page 119 and 120:
Management of Hyperglycemia in T2DM
Page 121 and 122:
AACE/ACE* Diabetes Algorithm For Gl
Page 123 and 124:
Dr. Alashbal’ s observation regar
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Management of hyperglycemia in type
Page 135 and 136:
Relevant comments on ADA/EASD algor
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 144 and 145:
Sequential insulin strategies in ty
Page 146 and 147:
ADA/EASD position statement 2012 In
Page 148 and 149:
ADA/EASD position statement 2012 L
Page 150 and 151:
Individualization of therapy ADA/EA
Page 152 and 153:
NICE Type 2 diabetes algorithm for
Page 154 and 155:
Relevant comments on NICE algorithm
Page 156 and 157:
Relevant comments on SIGN algorithm
Page 158 and 159:
Relevant comments on DoD/VA algorit
Page 160 and 161:
Comparison of the ADA/EASD algorith
Page 162 and 163:
Comparison of the ADA/EASD algorith
Page 164 and 165:
Pharmacotherapy of Type 2 Diabetes
Page 166 and 167:
Maximum blood glucose lowering effe
Page 168 and 169:
Dose-response relationships of sulp
Page 170 and 171:
Hazard ratios (95% CI) for differen
Page 172 and 173:
"metformin, sulfonylureas, • •
Page 174 and 175:
Efficacy of monotherapy Drug Thiazo
Page 176 and 177:
Insulin is the most effective diabe
Page 178 and 179:
Burdens of insulin therapy as a fir
Page 180 and 181:
Why health care providers and patie
Page 182 and 183:
Page 184 and 185:
The maximum period after which we m
Page 186 and 187:
Doctor, patient, and system barrier
Page 188 and 189:
Painful truth and big question why
Page 190 and 191:
Report of Institute for Quality and
Page 192 and 193:
Report of Institute for Quality and
Page 194 and 195:
Insulin glargine vs. NPH insulin In
Page 196 and 197:
Safety of Incretin-Based Therapies
Page 198 and 199:
The use of incretin-based glucose-l
Page 200 and 201:
Dr. Alashbal’ s observation regar
Page 202 and 203:
Conclusions The pendulum is swingin
Page 204 and 205:
Suggested seven deadly sins of drug
Page 206 and 207:
Never be And the first, this sin is
Page 208:
hank you Dr. Abdulameer Abdullah Al
show all

Consultant Physician

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?